161 related articles for article (PubMed ID: 25550411)
1. Obtaining reimbursement in France and Italy for new diabetes products.
Schaefer E; Schnell G; Sonsalla J
J Diabetes Sci Technol; 2015 Jan; 9(1):156-61. PubMed ID: 25550411
[TBL] [Abstract][Full Text] [Related]
2. Diabetes device reimbursement in the EU-5.
Schäfer E; Schnell G; Bobáková T
J Diabetes Sci Technol; 2013 Jul; 7(4):1084-92. PubMed ID: 23911192
[TBL] [Abstract][Full Text] [Related]
3. Reimbursement Pathways for New Diabetes Technologies in Europe: Top-Down Versus Bottom-Up.
Seidel D; Boggio Mesnil F; Caruso A
J Diabetes Sci Technol; 2019 Jan; 13(1):118-122. PubMed ID: 30033750
[TBL] [Abstract][Full Text] [Related]
4. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
5. Evidence for continuous glucose monitoring: sufficient for reimbursement?
Heinemann L; DeVries JH
Diabet Med; 2014 Feb; 31(2):122-5. PubMed ID: 24152416
[TBL] [Abstract][Full Text] [Related]
6. Considerations for an institution for evaluation of diabetes technology devices to improve their quality in the European Union.
Heinemann L; Freckmann G; Koschinsky T
J Diabetes Sci Technol; 2013 Mar; 7(2):542-7. PubMed ID: 23567012
[TBL] [Abstract][Full Text] [Related]
7. Use of relative effectiveness information in reimbursement and pricing decisions in Europe.
van Nooten F; Caro JJ
J Comp Eff Res; 2013 Jan; 2(1):33-44. PubMed ID: 24236519
[TBL] [Abstract][Full Text] [Related]
8. The role of reimbursement in the adoption of continuous glucose monitors.
Bartelme A; Bridger P
J Diabetes Sci Technol; 2009 Jul; 3(4):992-5. PubMed ID: 20144351
[TBL] [Abstract][Full Text] [Related]
9. Balancing adoption and affordability of medical devices in Europe.
Schreyögg J; Bäumler M; Busse R
Health Policy; 2009 Oct; 92(2-3):218-24. PubMed ID: 19410326
[TBL] [Abstract][Full Text] [Related]
10. Medical device reimbursement coverage and pricing rules in Korea: current practice and issues with access to innovation.
Lee SS; Salole E
Value Health; 2014 Jun; 17(4):476-81. PubMed ID: 24969010
[TBL] [Abstract][Full Text] [Related]
11. Future of diabetes-technology: certificate of competency for insulin pumps and continuous glucose monitors.
Heinemann L; Faber-Heinemann G; Roberts R; Walsh J
J Diabetes Sci Technol; 2012 Jul; 6(4):725-7. PubMed ID: 22920796
[No Abstract] [Full Text] [Related]
12. FACTORS INFLUENCING REIMBURSEMENT OF MEDICAL DEVICES IN FRANCE.
Loge P; Delalande F; Reymond MC; Germain S
Int J Technol Assess Health Care; 2015; 31(6):399-406. PubMed ID: 26868190
[TBL] [Abstract][Full Text] [Related]
13. Position statement on efficiency of technologies for diabetes management.
Martín-Vaquero P; Martínez-Brocca MA; García-López JM; ; ;
Endocrinol Nutr; 2014 Dec; 61(10):e45-63. PubMed ID: 25453400
[TBL] [Abstract][Full Text] [Related]
14. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
Persson U; Norlin JM
Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
[TBL] [Abstract][Full Text] [Related]
15. Reimbursement and coverage implications for CGM.
Aubry W
Diabetes Technol Ther; 2005 Oct; 7(5):797-800. PubMed ID: 16241886
[No Abstract] [Full Text] [Related]
16. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator-Comparison of Five European Healthcare Systems.
Fritzen K; Basinska K; Stautner C; Braun KF; Rubio-Almanza M; Nicolucci A; Kennon B; Vergès B; Hosny Y; Schnell O
J Diabetes Sci Technol; 2020 Mar; 14(2):262-270. PubMed ID: 31387385
[TBL] [Abstract][Full Text] [Related]
18. [Progress in the field of medical devices for diabetes].
Peters-Volleberg GW; Hilbers-Modderman ES; van den Berg Jeths A
Ned Tijdschr Geneeskd; 2001 Feb; 145(7):307-10. PubMed ID: 11234292
[TBL] [Abstract][Full Text] [Related]
19. Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective.
Cheung RY; Mui V
J Diabetes Sci Technol; 2015 May; 9(3):706-10. PubMed ID: 25697719
[TBL] [Abstract][Full Text] [Related]
20. Clinical review: Realistic expectations and practical use of continuous glucose monitoring for the endocrinologist.
Hirsch IB
J Clin Endocrinol Metab; 2009 Jul; 94(7):2232-8. PubMed ID: 19383778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
